# US 2021/0332047 A1 · Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332047 A1
- Document ID: US20210332047A1
- Status: Published application
- Kind: A1
- Application number: 17/103,631
- Filed: 2020-11-24
- Published: 2021-10-28
- Earliest claimed: 2004-05-13
- Assignees: ICOS Corporation
- Applicants: Icos Corporation
- Inventors: Edward A. KESICKI; Kerry W. FOWLER; Danwen HUANG; Hua Chee OOI; Amy OLIVER; Kamal Deep PURI; Fuqiang RUAN; Jennifer TREIBERG
- Web page: https://patentgrep.com/patent/US20210332047A1

## CPC

- C07D 473/34: attached in position 6, e.g. adenine
- A61K 31/52: Purines, e.g. adenine
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/48: of the pancreatic hormones
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 11/16: Central respiratory analeptics
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/91: with aryl or aralkyl radicals attached in position 2 or 3
- C07D 473/16: two nitrogen atoms
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim at position 2

27: A compound having the structure:
wherein
R1 is hydrogen, fluoro, chloro, methyl, or
R2 is hydrogen, methyl, chloro, or fluoro;
R3 is hydrogen, methyl, chloro, or fluoro;
R4 is hydrogen, fluoro, chloro, OH, OCH3, OCH2C≡CH, O(CH2)N(CH3)2, C(═O)CH3, C≡CH, CN, C(═O)NH2, OCH2C(═O)NH2, O(CH2)2OCH3; O(CH2)2N(CH3)2,
R5 is methyl, ethyl, propyl, phenyl, CH2OH, CH2OCH2C6H5, CH2CF3, CH2OC(CH3)3, CH2C≡CH, (CH2)3N(C2H5)2, (CH2)3NH2, (CH2)4NH2, (CH2)3NHC(═O)OCH2C6H5, or (CH2)4NHC(═O)OCH2C6H5; and
R8 is methyl, trifluoromethyl, chloro, or fluoro.

### Claim at position 3 (depends on 27)

28: The compound of claim 27, wherein
R1 is hydrogen or fluoro;
R2 is hydrogen or fluoro;
R3 is hydrogen,
R4 is hydrogen or fluoro;
R5 is methyl or ethyl; and
R8 is chloro or fluoro.

### Claim at position 4 (depends on 28)

29: The compound of claim 28, wherein the compound has the structure:

### Claim at position 5 (depends on 29)

30: The compound of claim 29, wherein the compound has the structure:

### Claim at position 6 (depends on 28)

31: The compound of claim 28, wherein the compound has the structure:

### Claim at position 7 (depends on 31)

32: The compound of claim 31, wherein the compound has the structure:

### Claim at position 8

33: A compound having the structure of formula (12)

### Claim at position 9

34: A compound having the structure of formula (173)
